

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit: 1632
)	
HANSSON, et al.)	Examiner: BERTOGLIO, V.
)	
Serial No.: 10/071,214)	Washington, D.C.
)	
Filed: February 11, 2002)	Date: March 8, 2004
)	
For: SCCE MODIFIED TRANSGENIC)	Docket No.: HANSSON=3A
MAMMALS AND THEIR USE AS)	
MODELS OF HUMAN DISEASES)	Confirmation No.: 9275

DRAFT CLAIM FOR DISCUSSION PURPOSESBY FACSIMILE (571-273-0725)

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop AF
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

A transgenic mouse having integrated within its genome a nucleotide sequence comprising

(1) a heterologous nucleotide sequence coding for an enzyme having serine protease activity and comprising the partial sequence glycine-X₁-X₂-isoleucine-isoleucine-aspartate-glycine (SEQ ID NO:14) where X₁ is aspartate or glutamate and X₂ is lysine or arginine, which

- a) hybridizes with the complementary sequence to the nucleotide sequence SEQ ID NO:1 under stringent hybridization conditions of 5-10°C under T_m, and/or
- b) has a 95% sequence identity to SEQ ID NO:1, and/or

(2) a heterologous nucleotide sequence which encodes the same amino acid sequence as that encoded by the heterologous nucleotide sequence of (1), operably linked to a SV40 promoter that drives expression of said heterologous scce in skin, wherein

USSN - 10/071,214

the mouse exhibits epidermal hyperplasia and hyperkeratosis and
a mild cellular inflammatory reaction to the skin.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
G:\ipc\n-q\Plou\Hansson3A\PTO DRAFT CLAIM.WPD